8-K: Shattuck Labs Announces Positive Phase 1 Data for SL-325

Shattuck Labs reports promising Phase 1 trial results for its SL-325 DR3 blocking antibody, with plans for a Phase 2b trial in Crohn's disease and advancement of its SL-846 bispecific candidate.

Summary

• Shattuck Labs announced positive data from its Phase 1 clinical trial of SL-325, a DR3 blocking antibody.
• The trial in healthy volunteers showed SL-325 was well-tolerated with a favorable safety profile.
• Only 3.7% of participants who received SL-325 developed low-titer antidrug antibodies (ADA) with no observed impact on pharmacokinetics (PK) or receptor occupancy (RO).
• Complete blockade of TL1A binding to DR3 was observed at doses of 0.1 mg/kg and higher, and this blockade was durable for over 3 months at doses greater than 1 mg/kg.
• A subcutaneous formulation of SL-325 has been developed, suggesting potential for quarterly dosing via an autoinjector pen.
• The company plans to initiate the RECEPTIVE-CD1 Phase 2b trial of SL-325 in moderate-to-severe Crohn's disease in the third quarter of 2026.
• The primary endpoint for the Phase 2b trial, endoscopic response at Week 12, is expected to be disclosed in the first half of 2028.
• Shattuck also provided an update on SL-846, a dual DR3 and IL-23 receptor blocking bispecific antibody candidate, with IND filing expected in the first half of 2027.
• The company announced that approximately 96% of warrants from a August 4, 2025 private placement were exercised, expected to yield approximately $54.9 million in gross proceeds.
• With existing cash and proceeds from warrant exercises, Shattuck expects to fund operations into 2029.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development due to strong Phase 1 data for SL-325, significant capital infusion from warrant exercises, and clear progression of the pipeline.

Positives

• SL-325 demonstrated a potentially best-in-mechanism immunogenicity profile with only 3.7% of participants developing low-titer ADA.
• Complete and durable blockade of TL1A binding to DR3 was achieved, supporting potential for extended dosing intervals (e.g., quarterly).
• SL-325 was well-tolerated across all dose levels with no serious treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs).
• The development of a subcutaneous formulation for SL-325 indicates potential for convenient administration.
• Initiation of the Phase 2b trial for SL-325 in Crohn's disease is scheduled for Q3 2026.
• IND filing for the SL-846 bispecific candidate is anticipated in the first half of 2027.
• Significant warrant exercises are expected to provide approximately $54.9 million in gross proceeds.
• The company projects sufficient capital to fund operations into 2029.

Negatives

• Antidrug antibodies (ADA) were detected in 3.7% of participants receiving SL-325, although at low titers and without observed impact on PK or RO.
• The Phase 2b trial primary endpoint (endoscopic response at Week 12) is not expected until the first half of 2028, a significant time away.

Risks

• The unpredictable relationship between preclinical study results and clinical study results.
• The timing or likelihood of regulatory filings and approvals.
• Global macroeconomic conditions and related volatility.
• Potential for changes in the company's capital resources and the time period over which they will be sufficient to fund operations.
• Risks and uncertainties identified in Shattuck's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2025.

Future Outlook

Shattuck Labs anticipates initiating its Phase 2b trial for SL-325 in Crohn's disease in Q3 2026, with primary endpoint data expected in 1H 2028. The company expects to file an IND for SL-846 in 1H 2027 and anticipates having sufficient capital to fund operations into 2029.

Management Comments

• "The profile of SL-325 is highly encouraging, including a potentially best-in-mechanism immunogenicity profile, saturation of DR3 at low doses of SL-325, and durable inhibition of TL1A binding for months after a single dose."
• "These data indicate that blocking DR3 with SL-325, or with our DR3 by IL-23 receptor blocking bispecific antibody candidate, SL-846, may substantially improve upon the efficacy shown to date with the TL1A inhibitor class, providing an opportunity to maximize potential efficacy for TL1A blockade in IBD and beyond."

Industry Context

StockSavvy.ai notes that Shattuck Labs' announcement positions it within the competitive landscape of inflammatory and immune-mediated disease treatments, particularly those targeting the TL1A/DR3 pathway. The positive Phase 1 data for SL-325, especially regarding immunogenicity and durability, could offer a competitive advantage over existing TL1A inhibitors. The advancement of SL-846, a bispecific targeting both DR3 and IL-23R, aligns with industry trends towards combination therapies and multi-target approaches for complex diseases.

Comparison to Industry Standards

• The reported ADA rate of 3.7% for SL-325 is significantly lower than ADA rates reported for some anti-TL1A antibodies in Phase 1 trials, which have ranged from 48% to 100% in some instances.
• The durability of DR3 occupancy for over 3 months at doses greater than 1 mg/kg for SL-325 suggests a potentially longer dosing interval compared to some biologics that require more frequent administration.
• Preclinical data for SL-846 demonstrated equipotent or superior in vitro potency compared to sequence equivalents of risankizumab (an IL-23 inhibitor) and icotrokinra (a TL1A inhibitor), positioning it competitively within its target therapeutic areas.

Stakeholder Impact

• Shareholders: Positive impact due to potential for increased company valuation from successful clinical trial progression and strengthened financial position from warrant exercises.
• Patients: Potential future benefit from new therapeutic options for inflammatory and immune-mediated diseases like Crohn's disease.
• Employees: Continued employment and potential growth opportunities as the company advances its pipeline and operations.
• Creditors: Improved financial stability due to increased capital, potentially reducing financial risk.

Next Steps

• Initiate RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn's disease in Q3 2026.
• Submit IND for SL-846 in the first half of 2027.
• Release safety and immunogenicity data for SL-846 in the second half of 2026.
• Disclose primary endpoint data for the RECEPTIVE-CD1 Phase 2b trial in 1H 2028.

Key Dates

Recommendation

The positive Phase 1 data and capital raise are encouraging, but the key value inflection points (Phase 2b data, IND for SL-846) are still some time away. The company's ability to execute on its clinical timelines and achieve positive outcomes in later-stage trials will be critical. Therefore, a 'hold' recommendation is appropriate pending further clinical de-risking.

Keywords

Shattuck Labs, SL-325, DR3 blocking antibody, Crohn's disease, Phase 1 clinical trial, Phase 2b trial, SL-846, biotechnology